Antam corrects report on use of public offering proceeds for 2015 ANTM-R rights issue
Bitget2026/10/08 13:49Antam issued a correction to its July 15, 2026 report on the use of proceeds from its ANTM-R rights issue. Net proceeds were IDR 5.35 trillion, with IDR 5.15 trillion reported as realized use of funds. Remaining IDR 203.29 billion was placed in deposits at Bank Syariah Indonesia at 6.5% and in a Bank Rakyat Indonesia giro account at 1.25%. Use-of-proceeds plan stayed centered on the Haltim Phase I ferronickel plant at IDR 3.49 trillion, with the balance for working capital and other projects. Working-capital and other-project spending was reported at IDR 1.66 trillion, versus a planned IDR 1.86 trillion. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PT Antam (Persero) Tbk published the original content used to generate this news brief via Indonesia Stock Exchange (IDX) (Ref. ID: 32164921) on October 08, 2026, and is solely responsible for the information contained therein.
- Antam issued a correction to its July 15, 2026 report on the use of proceeds from its ANTM-R rights issue.
- Net proceeds were IDR 5.35 trillion, with IDR 5.15 trillion reported as realized use of funds.
- Remaining IDR 203.29 billion was placed in deposits at Bank Syariah Indonesia at 6.5% and in a Bank Rakyat Indonesia giro account at 1.25%.
- Use-of-proceeds plan stayed centered on the Haltim Phase I ferronickel plant at IDR 3.49 trillion, with the balance for working capital and other projects.
- Working-capital and other-project spending was reported at IDR 1.66 trillion, versus a planned IDR 1.86 trillion.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canaccord Genuity: Lowers Oklo's target price to $66
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
Crypto prices
More
